NFATC2 and embryonal rhabdomyosarcoma: To determine the loss-of-function effects of NFAT1 on RMS cells, we showed that targeted disruption of NFAT1 by CRISPR/Cas9 in ERMS cells (381T and SMS-CTR) significantly reduced cell growth (Figure 4C).